Stockwinners Market Radar for July 24, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment bought 135.4K shares of Cameco today

19:43 EDT Expion360, Meyer Distributing enter distribution partnership - The company states: "Expion360 has expanded its sales and distribution partnership with Meyer Distributing, a leading national marketer and distributor of automotive and RV specialty products. Meyer's distribution network includes more than 90 warehousing facilities across the U.S. and Canada that service thousands of customers and hundreds of dealers. In addition to its broad reach, Meyer brings to Expion360 best-in-class supply chain technology and more than 38 years of experience managing vendor and customer relationships. The newly expanded partnership includes the assignment and special training of Meyer sales representatives focused on selling Expion360 products. Their training will help them assist RV dealers with configuring new and aftermarket e360(TM) battery power system installations. Meyer will also help manage logistics and distribution of Expion360 products to Expion360's growing portfolio of OEM customers." Shares of Expion360 are up 19% at $5.90 afterhours.

18:15 EDT Community Health to sell three Florida hospitals to Tampa General Hospital - Community Health Systems announced that subsidiaries of the company have signed a definitive agreement to sell 120-bed Bravera Health Brooksville in Brooksville, Florida, 128-bed Bravera Health Seven Rivers in Crystal River, Florida, 124-bed Bravera Health Spring Hill in Spring Hill, Florida, and their associated assets to Tampa General Hospital and certain of its affiliates for cash consideration of $280M, excluding anticipated purchase price adjustments for net working capital and the amount of capital leases assumed by the buyer. Total cash consideration to be received, inclusive of these items, is estimated to be approximately $290M. The transaction is expected to close later this year, subject to customary regulatory approvals and closing conditions.

17:48 EDT Fastly VP Shirk sells $126K in company shares - Fastly VP Brett Shirk disclosed the sale of 7,000 shares of company stock at $18.05 per share on July 20 for a total transaction value of $126,330.

16:41 EDT Boston Beer appoints Diego Reynoso CFO, Treasurer, effective September 5 - Boston Beer appointed Diego Reynoso as CFO and Treasurer, effective September 5. Reynoso most recently served as CFO of the Prepared Foods division of Tyson Foods, out of its Chicago office, from 2021 to 2023. He was previously Senior VP and CFO of the beer division at Constellation Brands and held various senior financial and operational roles at spirits company Beam Suntory . Earlier in his career, he held roles at Allied-Domecq, Danone, and Procter & Gamble. With Reynoso's appointment, Matt Murphy, who has served as Interim CFO, will resume his role of Vice President, Finance and Chief Accounting Officer, reporting to Reynoso.

16:38 EDT Cadence Bank sees noninterest expense reduction of $35M-$40M - Cadence Bank's initiaitves including the closure or consolidation of 35 branches and other strategic initiatives early retirements and other personnel efficiencies to occur primarily during Q3 are now projected to collectively reduce noninterest expense by approximately $35M-$40M annually, up from previous estimate of $15M-$20M.

16:30 EDT Salesforce CEO sells $3.4M in common stock - In a regulatory filing, Salesforce disclosed that CEO Marc Benioff sold 15K shares of common stock on July 21st in a total transaction size of $3.4M.

16:29 EDT F5 Networks up 9% at $163.70 after Q3 earnings beat and guidance

16:21 EDT TrueBlue backs FY23 capex view of $36M-$40M - Sees FY23 gross margin up 0 to 60 bps vs. prior view of down 20 to up 40 bps.

16:20 EDT M.D.C. Holdings raises quarterly dividend 10% to 55c from 50c per share - The dividend will be paid on Wednesday, August 23 to shareholders of record on Wednesday, August 9.

16:17 EDT Pennsylvania American Water to buy Greene County water system - Pennsylvania American Water, a subsidiary of American Water, announced that it signed an agreement with East Dunkard Water Authority to purchase its water system assets for $5 million. The system serves approximately 1,600 customers in Dunkard and Greene Townships and portions of Cumberland, Monongahela, Perry, and Whitely Townships, all located in Greene County, Pennsylvania - expanding the company's footprint to 38 counties across the Commonwealth.

16:14 EDT Zevia falls 10% to $3.80 after negative Q2 revenue pre-announcement

16:12 EDT AbCellera says U.S. Patent Office denies Berkeley Lights' request for rehearing - AbCellera announced that the United States Patent and Trademark Office's Patent Trial and Appeal Board has denied a rehearing request in an Inter Partes Review filed by Berkeley Lights, Inc. Berkeley Lights that challenged AbCellera's U.S. Patent No. 10,087,408. AbCellera's '408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells, an important part of AbCellera's end-to-end monoclonal antibody development engine.

16:10 EDT Whirlpool CEO says margins improved sequentially in Q2 - "We continue to build on our momentum with sequentially improved margins in Q2," said Marc Bitzer, chairman and CEO of Whirlpool. "Our portfolio transformation towards a higher-growth, higher-margin business is well underway, and we are well-positioned to benefit from housing-driven demand recovery, including now having 8 of the top 10 national builders as trade customers."

16:07 EDT MasterCraft Boat announces $50M share share repurchase authorization - MasterCraft Boat announced that its board of directors has authorized a new share repurchase authorization under which the company may repurchase up to $50M of its outstanding shares of common stock. The new authorization will become effective upon the expiration of the company's existing $50M share repurchase authorization.

16:06 EDT Acadia Pharmaceuticals names Kevin Oliver chief business officer - Acadia Pharmaceuticals announced the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023. Dr. Oliver will oversee all business development functions and will serve as a member of the company's Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia. "We are pleased to announce Kevin's appointment to lead our business development and partnering activities," said Steve Davis, Acadia's President and Chief Executive Officer. "Our recent successful launch of DAYBUE (trofinetide), the first and only drug approved for the treatment of Rett syndrome, together with the continued success of NUPLAZID (pimavanserin), the first and only drug approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, positions us to build on our first-to-market expertise as we further expand our franchises in rare disease and neuropsychiatry."

15:53 EDT Users indicate problems at Microsoft 365, says Downdetector - Reference Link

14:27 EDT 1st Source notified AGs on cybersecurity event estimated to impact 450K records - In a regulatory filing, 1st Source stated: "Per its Form 8-K filed July 10, 1st Source Corporation disclosed that, as part of the cybersecurity event concerning a software application known as MOVEit impacting numerous organizations and governmental agencies around the world, an unauthorized third-party gained access to sensitive data of commercial and individual clients, including personally identifiable information of individuals. The company summarized the steps it had taken to eliminate the software vulnerability and steps it was taking to notify and offer clients impacted complimentary monitoring, identity restoration, and fraud detection services. The company has since notified states attorney generals or other designated state officials as required under state data security notification laws of the incident, including the total estimated number of records impacted of 450,000 which includes the number of impacted residents in all applicable states."

13:36 EDT OncoCyte announces 1-for-20 reverse stock split - Oncocyte Corporation announced that the company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock. The reverse stock split will be effective at 5:00 p.m. Pacific time on July 24, 2023, and the company's common stock will begin to trade on a post-split basis at the market open on July 25, 2023, under the company's existing trading symbol "OCX". The CUSIP number for the common stock following the reverse stock split will be 68235C206. The reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Stock Market The reverse stock split was approved by the company's shareholders at a Special Meeting of Shareholders held on July 24, 2023, which authorized the Company to effect the reverse stock split at the discretion of the company's Board of Directors within certain parameters approved by the shareholders. The final split ratio was subsequently approved by the Company's Board of Directors at a meeting held on July 24, 2023.

13:05 EDT Biodexa Pharmaceuticals PLC-ADR trading resumes

12:46 EDT Ball Aerospace to design NCAR's next-gen weather radar antennas - Ball Aerospace has been selected to design the radio frequency front end system for the National Center of Atmospheric Research's Airborne Phased Array Radar program, the center's next-generation tool for gathering critical weather data. "The data APAR captures will change the way atmospheric scientists are able to understand and predict severe storm systems, and it will serve as an essential tool to help protect our communities from danger," said Paula Burns, vice president, Tactical Solutions, Ball Aerospace. "As a long-time partner on this project, our team at Ball Aerospace is excited to help bring APAR's capabilities to the weather community."

12:30 EDT ABVC BioPharma announces reverse stock split - ABVC BioPharma announced a reverse stock split of its common stock of one post-split share for every ten pre-split shares in an effort to regain compliance with Nasdaq's listing rules. The company expects the Reverse Stock Split to be effective as of 12:01 a.m. EST on July 25, 2023, authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock under the new CUSIP Number: 00091F 304. The company obtained shareholder approval for the Reverse Stock Split at a special meeting of shareholders on July 07, 2023 and the Company's board of directors approved the Reverse Stock Split ratio of 10 to 1. The principal purpose of the Reverse Stock Split is to decrease the total number of shares of common stock outstanding and hopefully, proportionately increase the market price of the common stock to meet the continued listing requirements of The Nasdaq Capital Market. The company's common stock will continue trading under the ticker symbol "ABVC." The Reverse Stock Split will not impact the rights or preferences of the company's common stock shares. The ownership percentage and voting power of each stockholder will remain virtually unchanged. No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders who would have received fractional shares due to their holdings not being evenly divisible by the reverse stock split ratio will receive shares rounded up to the nearest whole number. The company's Board of Directors expressed that they aim for the Reverse Stock Split to not only enable the company to meet the NASDAQ listing requirements, but also to lead the company out of the 'Penny Stock' category. The Board further emphasized, "We believe this reverse stock split can have a positive impact on the Company's market valuation, creating a solid foundation for growth. By improving our financial standing, we aim to instill confidence in our investors and attract a broader investor base. Ultimately, we strive to establish a more stable financial platform to attract investors and enable us to pursue our research and development activities with greater stability."

12:00 EDT Biohaven falls -6.3% - Biohaven is down -6.3%, or -$1.61 to $23.83.

12:00 EDT Lifezone Metals falls -16.7% - Lifezone Metals is down -16.7%, or -$1.80 to $9.00.

12:00 EDT Posco rises 18.3% - Posco is up 18.3%, or $19.36 to $125.05.

11:52 EDT Fed fines UBS $268.5M for Credit Suisse's Archegos credit risk - The Federal Reserve Board announced a consent order and a $268.5M fine with UBS Group for misconduct by Credit Suisse, which UBS subsequently acquired in June. The misconduct involved Credit Suisse's "unsafe and unsound" counterparty credit risk management practices with its former counterparty, Archegos Capital Management, the agency said in a statement. Reference Link

11:47 EDT United Therapeutics says wins appeal in dry powder inhaler patent litigation - United Therapeutics (UTHR) announced that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc (LQDA). The Federal Circuit affirmed that Liquidia's proposed Yutrepia product infringes a United Therapeutics' patent, U.S. Patent No. 10,716,793. As a result, the U.S. FDA cannot grant Liquidia final approval for its Yutrepia product until expiration of the '793 patent, May 14, 2027, except in certain circumstances. The Federal Circuit affirmed the district court's decision that Liquidia would induce infringement of various claims of the '793 patent by marketing Yutrepia and that Liquidia failed to prove any claim of that patent invalid. The '793 patent relates to a method of administering treprostinil via inhalation. The Federal Circuit also affirmed the district court's decision that certain claims of another United Therapeutics patent, U.S. Patent No. 9,593,066 (the '066 patent), are either invalid or not infringed by Liquidia. The '066 patent relates to a method of making treprostinil, the active pharmaceutical ingredient in both Tyvaso Inhalation Solution and Tyvaso DPI Inhalation Powder. "Today's decision vindicates our position, as confirmed earlier by the district court, that Yutrepia is an infringing product. We will continue to vigorously defend our intellectual property," said Shaun Snader, Vice President and Associate General Counsel - IP and Litigation at United Therapeutics.

11:34 EDT Richardson Electronics completes upgrades to LaFox, Illinois headquarters - Richardson Electronics announced the completion of recent upgrades to its LaFox, IL Headquarters after investing several million dollars to expand its design, manufacturing and test capabilities and capacity. The expansion adds more than 16,000 square feet of manufacturing space and will serve as a showcase for the Company's Green Energy Solutions production. Richardson Electronics will manufacture its patented ULTRA3000 and ULTRAPEM multi-brand Pitch Energy Modules; the patent-pending ULTRAUPS3000, designed to replace lead-acid batteries in wind turbine generators and other power management applications; battery start modules for numerous applications including EV locomotives; and other products in the expanded area. Total manufacturing space in LaFox is now 160,000 square feet.

11:10 EDT Meta Platforms to expand access to Instagram Subscriptions - Instagram is expanding access to its Subscriptions feature. Meta's Instagram said on a blog post that, "We introduced Instagram subscriptions as one of those tools last year, giving creators in the U.S. a new way to deepen connections with their most engaged followers while unlocking recurring monthly income. After seeing the value that subscriptions can offer to creators in the U.S., we're expanding access to the feature to more creators around the world. In the coming weeks, eligible creators in Australia, Brazil, Canada, France, Germany, Italy, Japan, Mexico, Spain and the United Kingdom will be able access to Subscriptions and start earning through support from their fans. We plan to continue rolling out access globally in the coming months.Reference Link

10:31 EDT Bion reports start up of livestock waste treatment tech demonstration project - Bion Environmental Technologies announced that it has initiated integrated system startup at its Fair Oaks, Indiana, demonstration and optimization facility. Bion said: "The system will allow Bion to demonstrate the effectiveness of its core ammonia recovery technology at commercial scale. Bion will operate the integrated Ammonia Recovery System in 'startup mode' for approximately one week, running liquids to check for pressure integrity and establish baselines. Once the startup phase is complete, the system will begin processing digestate, the manure residual after methane has been extracted through anaerobic digestion. Bion anticipates 3-4 weeks to achieve steady state operations and 4 to 12 weeks to produce repeatable operating data that is consistent with the requirements needed to support the existing economic models."

10:11 EDT Paragon Technologies calls level of Ocean Power board compensation 'egregious' - Paragon Technologies owns approximately 4.0% of the outstanding shares of Ocean Power Technologies. Paragon said, "On July 11, OPT issued a response to Paragon's public letter released that morning. Yet again, rather than respond to the alarming and factual statements Paragon has made regarding OPT's historic financial losses and rapidly degrading balance sheet, management and the Board continue to paint lipstick on OPT's business.On July 12, OPT announced its Fiscal 2023 results. In announcing the highlights for the year, CEO Philipp Stratmann touts the 'best year of revenue generation since fiscal 2015' and 'positive gross margin for the first time since fiscal 2016.' What management FAILED to even mention or explain is the $28 million in annual expenses, up almost 35% year over year. Management failed to talk or explain the $26 million net loss in fiscal 2023, up almost 40% year over year. OPT recently told shareholders that its 'Board is actively engaged in overseeing management's execution of the Company's strategy and is comprised of six highly qualified directors, five of whom have been appointed in the last three years.'...OPT's newly refreshed Board and CEO have indeed delivered for shareholders - delivered a disastrous record. In the past three years, nearly $50 million in cash has been burned to achieve: Record losses of almost $60 million; Less than $6 million in total revenues; Despite the staggering and unjustifiable destruction of OPT shareholder value, the Board has seen itself fit to reward itself in a manner that we believe is self-serving and detrimental to shareholders while the business strategy bleeds OPT dry...In Fiscal 2018, total board and NEO compensation was 390% - nearly four times - of OPT sales. In Fiscal 2019, total such compensation was 260% of sales. OPT has compensated its directors and named executive officers more money than the company is generating in total sales! The level of Board compensation is egregious and an insult to shareholders in the worst possible way. Sadly shareholders should not be surprised as this Board appears to believe it is entitled to do what it wishes with the Company's assets as it touts the purported amazing progress the Company has made. Paragon hereby demands that OPT's directors return all excessive Board compensation to the Company over the past ten years since the present Chairman Terence Cryan has been on the Board.Recent precedent has come down in favor of shareholders when Board compensation has been excessive as evidenced by the recent return of $735 million in board compensation from Tesla board members. Paragon believes that OPT's Board has violated the most fundamental fiduciary obligation that directors are required to uphold, its duty of care in doing what is in the best interests of shareholders. On behalf of all shareholders, Paragon intends to hold the Board accountable to the fullest extent of the law."

10:04 EDT Sodexo to acquire A.H. Management, terms not disclosed - With the acquisition of A.H. Management,Sodexo will extend InReach's offerings in the fast-growing North American convenience market. A.H. Management, the premier convenience solutions operator in the Chicago region and Southeast Wisconsin, is one of the largest operators in the Mid-West. The company said, "Sodexo accelerates its food transformation strategy to address fast-changing consumer needs and behaviors in hybrid working environments and will expand its convenience offering by reinforcing its territorial footprint in North America. This latest move reflects Sodexo's strategy to renew existing food models and to reinvent on-site food offers. This new acquisition represents a further step in the food transformation for Sodexo in North America. A.H. Management will follow the acquisition of Frontline Food Services in 2022, as well as the food tech start-up Foodee and the commissary kitchen model Nourish. Inc in 2021. With A.H. Management, Sodexo will complement and broaden its multi-channel offerings through InReach including micro markets, vending, office coffee, pantry, water, catering, fresh food and on-site food service in the Mid-West, Northern Illinois and Southern Wisconsin, as well as the Chicago and Milwaukee metropolitan areas. A.H. Management is a family-owned business that began in 1939 serving clients in all business segments. Through the years, the business has grown to be one of the largest independent operators in the U.S and has a strong reputation for customer service excellence." The closing of the acquisition is expected in the coming months.

10:00 EDT Lifezone Metals falls -5.4% - Lifezone Metals is down -5.4%, or -58c to $10.21.

10:00 EDT Sunlands Online falls -7.1% - Sunlands Online is down -7.1%, or -34c to $4.51.

10:00 EDT AMC Entertainment rises 16.8% - AMC Entertainment is up 16.8%, or 74c to $5.14.

09:59 EDT BioNexus Gene Lab Corp trading resumes

09:54 EDT BioNexus Gene Lab Corp trading halted, volatility trading pause

09:53 EDT Bluejay Diagnostics Inc trading halted, volatility trading pause

09:47 EDT Livent falls -4.0% - Livent is down -4.0%, or -$1.06 to $25.47.

09:47 EDT Sunlands Online falls -7.1% - Sunlands Online is down -7.1%, or -34c to $4.51.

09:47 EDT TLG Acquisition One rises 17.6% - TLG Acquisition One is up 17.6%, or $1.75 to $11.70.

09:40 EDT Afya begins negotiation of non-sponsored Brazilian Depositary Receipts - Afya announced the start of negotiation of its non-sponsored Brazilian Depositary Receipts, with a 1-for-2 stock split, aimed to provide investment opportunities on Afya for Brazilian investors.

09:24 EDT 22nd Century implements $15M cost reduction initiative - The Company has implemented a cost savings initiative intended to simplify operations as it continues to tighten its focus on key end markets and operating strategies resulting in an estimated $15 million in annualized cost reductions across its operations once fully in place.

09:22 EDT 22nd Century adds Andy Arno to board of directors - The Company announced the addition of capital markets veteran Andy Arno to its Board of Directors. Arno previously served, until February 2023, as Vice Chairman of The Special Equities Group, a division of Dawson James Securities, Inc., plus other senior roles at investment banking firms.

09:20 EDT Inspira Technologies receives ISO 13485:2016 required for EU regulatory approval - InspiraTechnologies OXY announced it has received International Organization for Standardization, or ISO, 13485:2016 Standard Certification, which is the international standard for quality management systems within the medical device industry, and a requirement for EU regulatory approval. The ISO certification encompasses key aspects, including design, development, manufacturing, distribution and sales of extracorporeal and blood monitoring devices and respiratory care devices. The ISO certification process also involved a comprehensive evaluation of the Company's quality management system, including documentation, risk management and continuous improvement practices. The assessment was conducted by the British Standards Institution Group, an independent, third-party auditing firm specializing in medical device quality management systems.

09:17 EDT Kartoon Studios announces sell through of Stan Lee digital collectible - Kartoon Studios announced a total and near-instantaneous sell through of Stan Lee digital collectibles through its partnership with VeVe, on July 18. The total drop, of over 8,000 digital collectibles opened at 8am PST, and was sold out almost immediately. This news comes on the heels of a successful opening of the Stan Lee Exhibit at The Comic-Con Museum in San Diego, California.

09:16 EDT Muscle Maker reports top-line revenue over $45.7M in June - Muscle Maker announced that Sadot crossed the $500M total revenue since inception milestone by achieving top line revenue of over $45.7M for the month of June 2023. The announcement marks the eighth consecutive month in which top line revenue has exceeded $45M and shows continued success of Sadot with total revenue since inception in November 2022 of over $515M.

09:09 EDT Gevo signs MSA with subsidiary of McDermott for SAF facilities - Gevo announces it entered into a Master Services Agreement, MSA, with a subsidiary of McDermott International to provide front end engineering and early planning services for Gevo's development of multiple sustainable aviation fuel, SAF, facilities in North America. The first facility, Net-Zero 1, is expected to be located near Lake Preston, South Dakota. The Net-Zero 1 plant is expected to produce up to 65 million gallons of sustainable aviation fuel, diesel, renewable gasoline that, when consumed, is designed to have a lifecycle net-zero greenhouse gas footprint. Under the scope of the MSA, McDermott will provide engineering, execution planning and pricing for the engineering, procurement, and construction phase of Gevo's Net-Zero 1 project. "Gevo's Net-Zero Plant Design with its focus on carbohydrates as feedstock, has been carefully chosen for its exceptional cost-effectiveness, reliability, and scalability to meet the surging demand for sustainable aviation fuel and renewable hydrocarbons. This MSA is the first step towards adding McDermott as a project EPC partner. In addition to Axens, Praj, and Fluid Quip, adding McDermott to our team, fortifies further our capabilities in project execution and modularization, especially when teamed with Praj. In an increasingly challenging project environment over the past years, this collaboration is designed to ensure we stay on track, manage costs, execute our NZ-1 project, and be capable of executing additional NZ projects," stated Dr. Chris Ryan, President and Chief Operating Officer of Gevo.

09:07 EDT Great Lakes receives Notice to Proceed with agreement with NextDecade - Great Lakes Dredge & Dock Corporation (GLDD) announced the receipt of Notice to Proceed to perform essential improvements to the Brownsville Ship Channel for NextDecade Corporation's (NEXT) Rio Grande LNG project. The work includes deepening the entrance channel to the western end of the RGLNG property also known as Phase 1 of the Brazos Island Harbor Channel Improvements. This also includes the development of two ship berths and turning basin for the Rio Grande LNG facility. Lasse Petterson, Great Lakes' President and Chief Executive Officer commented, "This exciting milestone project is the largest undertaken by Great Lakes in its 133-year history. We look forward to working with NextDecade and other stakeholders, including the U.S. Army Corps of Engineers and the Port of Brownsville, on this important improvement project that will benefit the navigation interests and allows for future development of the Port of Brownsville. Our proven performance and safety culture allows us to support the growth of LNG export in the U.S., which is a necessity in balancing affordability for energy and overall sustainability."

09:06 EDT Castor Maritime announces completion of the sale of the M/V Magic Twilight - Castor Maritime announces that on July 20, 2023, the Company completed the previously announced sale at a price of $17.5 million of the M/V Magic Twilight, a 2010-built Kamsarmax, by delivering the vessel to its new owner. The Company expects to record during the third quarter of 2023 a net gain on the sale of the M/V Magic Twilight of approximately $4.0 million, excluding any transaction related costs.

09:04 EDT Five Star Bank promotes Scott Bader to CISO - Financial Institutions, parent company of Five Star Bank, SDN Insurance Agency, and Courier Capital, announced that Scott Bader has been promoted to Senior Vice President and Chief Information Security Officer, CISO, of the Bank. In his role, Bader will be responsible for the execution and evolution of the Bank's comprehensive information and cybersecurity program, as well as compliance with statutory and regulatory requirements regarding information access, security and privacy.

09:03 EDT Heron Therapeutics announces restructuring, cost reduction plan - Heron Therapeutics announced a cost reduction plan and a corporate restructuring, following a strategic review of the business conducted by the new management team. These actions are expected to result in cash savings of approximately $75M through 2025, inclusive of $45M in operational savings, and continue Heron's progression towards a streamlined organization focused on commercial execution, enabling it to take a crucial step towards achieving profitability. The company's cost reduction plan will focus on streamlining operational expenditures, including reductions in research and development and general and administrative expenses, while aiming to achieve profitability in late 2024. A portion of the expected cash savings will come from reduced external spend, including completed renegotiation and right-sizing of key vendor contracts, which is expected to result in over $31M in cash savings through 2025. In addition, Heron has conducted a corporate restructuring, reducing the company's employee base by 25%. Due to this restructuring, Heron expects to incur non-recurring cash expenses of approximately $5.9M in 2023.

08:56 EDT Lytus Technologies launches payments gateway for Indian customers - Lytus Technologies Holdings has announced the launch of its payments gateway for Indian consumers. This marks the entry of Lytus Technologies into the Indian fintech market through the introduction of its payments gateway offerings to businesses in the Indian cable and broadband sector. Lytus Technologies entered the Indian market with its Telecast & Multicast and broadband services and recently acquired a 51% stake in Sri Sai Cable and Broadband Private Limited in Telangana, India. With the strategic aim of expanding its footprint in India by offering diverse services to Indian consumers, the launch of the payment gateway will provide an additional boost to the company in the market. Initially, Lytus consumers using IPTV and broadband services will enjoy the convenience of the new payment gateway, facilitating their transactions.

08:55 EDT Williams Industrial files for Chapter 11, to be acquired for $60M - Williams Industrial Services announced that it and certain of its subsidiaries have filed voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware and agreed to sell substantially all of the company and its subsidiaries assets to EnergySolutions for $60M. The company and EnergySolutions have entered into a purchase agreement pursuant to which EnergySolutions will acquire substantially all the assets and assume certain ordinary course operating liabilities of the company and its subsidiaries for $60M. These assets represent the company's nuclear, fossil, energy delivery, and paper mill operations, which have continued to perform profitably and have strong prospects for future growth. EnergySolutions is not acquiring the Company's operations connected to its water contracts in Florida and Texas. In order to provide necessary funding during the Chapter 11 proceeding, the Company has received commitments for two debtor-in-possession financing credit agreements with its prepetition lenders. Upon approval by the Bankruptcy Court, the DIP financing agreements are expected to provide the Company with the necessary liquidity to permit the businesses that will be disposed of to operate in the normal course and meet their obligations to their employees, vendors and customers throughout the Chapter 11 proceeding while executing on the sale process of the businesses for which EnergySolutions is the "stalking horse" bidder. One of the company's DIP facilities will be a revolving line of credit which will replace the company's prepetition RLOC, allowing for continued credit advances based on the company's collateral contributions up to a maximum availability of $12M. The second facility is a delayed draw term loan with the company's existing term lenders which will provide up to $19.5M of incremental liquidity following the petition filing. The transaction with EnergySolutions is part of a sale process under Section 363 of the Bankruptcy Code in which EnergySolutions is the "stalking horse" bidder, meaning that the purchase agreement between the Company and EnergySolutions contains the terms against which competing offers will be solicited and evaluated during a Chapter 11 auction process. The company is seeking Bankruptcy Court approval of bidding procedures allowing for the submission of higher or otherwise better offers, and is seeking to consummate a sale by September 30, subject to Bankruptcy Court approval. The company will manage the bidding process and evaluate any bids received, in consultation with its advisors and otherwise in accordance with the bidding procedures and oversight by the Bankruptcy Court. Under the purchase agreement, EnergySolutions will not acquire the company's operations connected to its water contracts in Florida and Texas. The company is not currently projecting any return for its stockholders or for certain creditors of the retained water business. The factors that precipitated the company's Chapter 11 filing and sale process included: the loss of customer contracts in early 2022 that comprised 19% and 20% of the company's annual revenue and gross profit, respectively, in 2021 and the accompanying loss of $361M in backlog for 2022 and later years; more than $15 million of operating losses associated with the Company's water operations from 2021 through 2023 year to date; approximately $8M of start-up costs and operating losses related to the company's entry into the transmission and distribution market from early 2021 through the first quarter of 2023; and the inability of the company to convert enough pipeline into revenue and to cut enough costs to overcome these losses and corresponding liquidity challenges. As previously announced, the company undertook actions to improve the performance of its business, including an aggressive move to trim operating expenses, the implementation of a plan to shorten collection times on accounts receivable, and an attempt to expand into the transmission and distribution market. However, those moves were insufficient to position the business for profitability.

08:39 EDT Solitario updates progress on Florida Canyon, Lik Zinc projects - Solitario Resources (XPL) announced the commencement of the 2023 work programs on its Florida Canyon zinc project in Peru and Lik zinc project in Alaska. Highlights of the planned 2023 program include drilling on both the Florida Canyon and Lik projects, and a new multi-year community agreement at Florida Canyon to support continued exploration. Florida Canyon is held in a joint venture between Solitario and Nexa Resources (NEXA). The Lik project is held in a joint venture between Solitario and Teck American Incorporated (TECK). Florida Canyon: Drilling is expected to begin at Florida Canyon by mid-August. Approximately 4,000 meters of core drilling is planned with the initial exploration targets being extensions of the high-grade Florida Canyon zinc deposit to the south. Additional drilling may be conducted in other areas in and around the Florida Canyon deposit. Importantly, Nexa recently signed a community agreement that allows for continued exploration on the property to the end of 2025 and paves the way for the completion of an access road to local communities and active project areas. Several communities currently do not have road access and this agreement will significantly improve community safety and provide new opportunities for sustainable commerce in the future. Permitting is nearly complete to significantly expand the area for drilling in 2024 and beyond. The new application will enlarge the area permitted for drilling by approximately 500 percent where over 80 new drill sites are proposed in areas to the south, east and southeast of the Florida Canyon deposit. Multiple drill holes can be completed from each site. Two multi-kilometer trends identified over the last two years of field work have undrilled high-grade zinc mineralization at surface comparable to the surface mineralization at Florida Canyon. Lik Zinc Project: Drilling is anticipated to start at Lik in mid-August. Two step-out core holes are planned totaling over 700 meters. These two holes test for extensions of previously defined mineralization on the northeastern margin of the currently known resource footprint. In addition, 120 line-kilometers of helicopter-borne ZTEM geophysical surveys will measure conductive features at depth. Flight-lines traversing the entire Lik property position will be spaced every 200 meters. ZTEM is an efficient and cost-effective geophysical method to define deep mineralization and will contribute to a better understanding of the down-dip continuation of the Lik deposit and other potential deeper mineralization below the Kelly River thrust plate. Terms of the Florida Canyon: Solitario owns a 39% interest in the Florida Canyon project with Nexa owning a 61% interest. Nexa can earn a 70% interest in the Florida Canyon project by continuing to independently fund all project expenditures and committing to place the project into production based upon a positive feasibility study. After earning 70%, and at the request of Solitario, Nexa has further agreed to finance Solitario's 30% participating interest for construction through a project loan. Solitario will repay the loan facility through 50% of its net cash flow distributions for production on Florida Canyon joint venture properties.

08:37 EDT NewtekOne appoints Chandler as Director of Operations - NewtekOne (NEWT) announced that Newtek Bank, N.A. has recruited Burt Chandler as Director of Operations, effective today. Chandler comes to Newtek Bank with over 35 years of banking experience across all facets of banking operations. Chandler most recently was the Senior Vice President and Director of Central Deposit Operations at BancorpSouth/Cadence Bank (CADE).

08:36 EDT Rexford Industrial acquires industrial property for $210M - Rexford Industrial Realty announced the acquisition of an industrial property for a purchase price of $210M. The acquisition was funded using proceeds from forward equity settlements of which the company now has approximately $448M remaining for settlement. The company acquired 9400 Santa Fe Springs Road, Santa Fe Springs, located in the LA - Mid-Counties submarket for $210M, or $353 per square foot. Situated on 22.4 acres and 100% leased to two tenants, the 595,304 square foot building delivers a high degree of functionality within a submarket demonstrating an extreme scarcity of similar size and quality available product. The investment generates an initial unlevered cash yield of 5.0% projected to grow to an unlevered stabilized cash yield on total investment of 6.2% through re-leasing at market rents and contractual annual rent increases of 4.0%.

08:35 EDT Color Star subsidiary and Times Capital enter into a partnership - Color Star Technology announces that its subsidiary, Color Metaverse Pte. and Times Capital Research have entered into a framework strategic partnership agreement to work on gathering investments to Color Metaverse's various live event projects. Under the new agreement, Color Metaverse expects to increase box office revenue while also boosting commercial income through investments and commercial sponsorships.

08:34 EDT Freightos reports 239,000 transactions booked on platform in Q2, up 59% y/y - Freightos reported Q2 Key Performance Indicators. A record 239,000 transactions were booked on the platform in Q2 2023, up 59% from Q2 2022, continuing Freightos' streak of record transactions. This strong growth, against the backdrop of an ongoing freight market downturn, demonstrates the momentum of Freightos' mission to digitalize international freight. As a result of reduced market freight rates, Gross Booking Value was below management expectations. Transactions growth was supported by a 10% year on year growth in Unique buyer users, reaching 16,438. Carriers selling on the platform remained stable at 37 in Q2 2023. In early July, in response to the international freight market downturn, the company announced an operational efficiency plan, which is expected to improve Adjusted EBITDA by about $5.6M dollars per year, with the aim of ensuring the company's ability to reach break-even on existing cash reserves despite the softer market.

08:33 EDT AgriFORCE continuing to explore areas to remove 'non-essential' expenses - AgriFORCE Growing Systems provided a business update following the recent restructuring of management. Richard Wong, interim CEO of AgriFORCE, stated, "We remain committed to pursuing business opportunities that drive organic growth, positive cash flow, and value for our shareholders. To assist with our growth strategy, we are reallocating our resources to focus on the commercialization of our products and are analyzing the food verticals best suited for our IP. With the current senior management team of Mauro Pennella, Troy McClellan, and Hernando Ruiz-Jimenez in place, we are well-positioned to execute on our business growth initiatives and drive near-term revenue for UN(THINK) Foods, AgriFORCE-RCS, and monetization of our patented GrowHouse. We look forward to reaching significant milestones and providing updates to our shareholders along the way. Importantly, we have reduced our average monthly operating cash burn by approximately 31% since year end and continue to explore areas where we can remove non-essential expenses," continued Mr. Wong. "Finally, we are working to complete our previously announced acquisitions and are progressing through due diligence."

08:31 EDT Imax announces $35M debut for 'Oppenheimer' - Imax exploded to one of the company's biggest weekends ever at the global box office on the strength of Christopher Nolan's "Oppenheimer", delivering a massive $35M debut on only 740 screens worldwide. The stunning figure represented IMAX's biggest share ever of a film's global opening weekend box office with 20% of total receipts.

08:31 EDT DarioHealth announces agreement with large regional health plan - DarioHealth announced a new agreement with a large regional health plan to deliver highly personalized digital health solutions to more than 160,000 Plan members living with hypertension. The Plan is set to launch in late July 2023. The Plan selected Dario's digital solution for hypertension, part of the Company's cardiometabolic product suite, to engage the Plan's members with a highly personalized and consumer-centric approach to managing hypertension. Dario's solution is proven to improve clinical outcomes and keep members engaged over time, and a streamlined implementation process made it easy for the Plan to launch and scale the program across eligible members.

08:25 EDT Ondas announces noteholder elects to purchase $11.5M of convertible notes - Ondas Holdings announced that a note holder has elected to purchase $11.5M in aggregate principal amount of 3% senior convertible notes due 2025 resulting in gross proceeds of $10M to Ondas Holdings. Oppenheimer & Co. Inc. will act as placement agent in connection with the Offering. Also, if elected by the note holder, Ondas Holdings may complete additional closings of up to an additional $34.5M in aggregated principal amount. The proceeds from the investment in Ondas Holdings will be used for general corporate purposes. In addition, the Company and the note holder agreed to extend the maturity of the existing convertibles notes originally issued in October 2022 to April 2025. Ondas Holdings also announced that its subsidiary Ondas Networks has received $11.5M in an initial closing of a previously announced investment from a private investor group led by Charles & Potomac Capital. The C&P Group plans to invest an additional $3.5M in Ondas Networks under the same terms within thirty days.

08:22 EDT Dallas Cowboys, GCN celebrate 'success' of 'Dallas Cowboys Game Time' tournament - The Dallas Cowboys and GCN announce the success of the first-ever Dallas Cowboys Game Time Tournament, powered by Lenovo. This groundbreaking Fortnite tournament, featured more than 300 participants and captured the attention of gaming enthusiasts with 11,347 concurrent viewers and a total of 133,211 unique views during the live stream.The finals saw 93 players compete for an unforgettable trip to the Super Bowl LVIII. Building on the triumph of the first tournament, GameSquare is excited to announce the Finals of the Dallas Cowboys Game Time Tournament 2, featuring Rocket League. The Finals are scheduled for Thursday, July 27, 2023, starting at 3:00 PM Central. Spectators can tune in to the action on the official Dallas Cowboys YouTube channel.

08:21 EDT Fintech Ecosystem Development extends deadline to complete combination - Fintech Ecosystem Development announced that its board of directors has decided to extend the date by which the Company must consummate an initial business combination from July 21, 2023, for an additional month, to August 21, 2023, and that its sponsor, Revofast deposited $110,000 into the Company's trust account in connection with this extension, the fourth of twelve potential one-month extensions of the Deadline Date available to the Company. The Company's Amended and Restated Certificate of Incorporation, as amended, provides the Company with the right to extend the Deadline Date up to twelve times for an additional one month each time, from April 21, 2023, to up to April 21, 2024.

08:19 EDT Keros Therapeutics to host conference call on KER-012 Phase 2 trial - Keros Therapeutics announced that Keros will host a conference call and webcast to provide an overview of TROPOS, its global Phase 2 clinical trial to evaluate KER-012 in combination with background therapy in patients with pulmonary arterial hypertension, on August 8, 2023 at 8:00 a.m. Eastern time. "PAH is a debilitating disease potentially driven by imbalanced signaling of the transforming growth factor-beta family of proteins, with no treatments available that halt or reverse the disease's progression. The predicted mechanism-of-action of KER-012-based on preclinical and Phase 1 clinical data-suggests that KER-012 could potentially correct dysfunctional activin signaling in PAH without a dose-limiting red blood cell effect," said Dr. Mardi Gomberg-Maitland, M.D., M.Sc., Chief Clinical Research Officer, School of Medicine Health Sciences at George Washington University and the Director of the Pulmonary Hypertension Program. "The TROPOS trial offers hope for improving and potentially extending the lives of those suffering from this devastating disease."

08:16 EDT Panbela Therapeutics opens enrollment in UK, Germany for ASPIRE trial - Panbela Therapeutics announced it has opened enrollment in the UK and Germany for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. "We're thrilled to bring on the UK and Germany for the ASPIRE trial and to now have the full complement of Countries open and actively enrolling," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "Next up, we are focused on having all sites open for enrollment within the next couple months, and then towards the interim data analysis in early 2024."

08:16 EDT ONCAP completes investment in Biomerics, merger with Precision Concepts - ONCAP closed a significant investment into Biomerics and provided a material realization for investors in Precision Concepts including ONCAP IV. As part of the transaction, Biomerics has merged with the medical business of ONCAP IV's current portfolio company, Precision Concepts including Precision Concepts Group of Winston-Salem, NC, which was acquired from the Marino family in April 2023. This investment has been made in partnership with Biomerics' founder and CEO Travis Sessions, current Biomerics shareholder Wasatch Equity Partners, and the Marino family. Following this transaction, Precision Concepts will become a stand-alone pure-play consumer packaging company with a dedicated focus from the existing management team on growing both organically and through mergers and acquisitions/ The investment in Biomerics was made by a combination of ONCAP IV, ONCAP V and co-investors. With the completion of this transaction, Biomerics is the second investment for ONCAP V alongside Right At School, which closed earlier this month. Proceeds to Precision Concepts were used to repay debt and provide a significant distribution to shareholders, including ONCAP IV. Following this transaction, Biomerics has over 1.2 million square feet of manufacturing space across 13 locations making it one of the Top 10 interventional contract development and manufacturing organizations globally. Biomerics supplies 22 of the top 35 medical device OEMs and is strategically focused on high growth end markets including structural heart, electrophysiology, robotic surgery, cardiovascular disease, and endoscopy. The merger furthers Biomerics' fully integrated capability set and positions it to best serve its OEM customers. Going forward, Biomerics will be well-capitalized with significant capacity to continue to pursue strategic M&A. The Precision Concepts management team, led by CEO Ray Grupinski, will continue to operate the consumer packaging business, which possesses strong EBITDA margins and an attractive growth profile. We believe this transaction helps to simplify and focus the remaining Precision Concepts business, better positioning it for a successful exit in the future.

08:15 EDT SmileDirectClub expands new premium CarePlus offering - SmileDirectClub announced its premium aligner offering, CarePlus, will be available at all U.S. SmileShop and select Partner Network locations beginning in August, giving consumers even more choices on how to begin and navigate their Smile Journey. "CarePlus reflects our commitment to giving customers choice, which has always been central to our mission to create innovative solutions for traditional orthodontics," said David Katzman, CEO and Chairman, SmileDirectClub. "Customers appreciate the flexibility of CarePlus and the extra confidence that comes with having a local licensed dentist available for an in-office visit, in addition to the virtual care platform. This offering is an incremental growth channel that's a natural extension of what we do best as a customer-driven company."

08:13 EDT Unifund to become public through Everest Consolidator combination - Everest Consolidator Acquisition (MNTN) and Everest Consolidated Sponsor have entered into a definitive business combination agreement with Unifund Financial Technologies, a group of data science and analytics companies operating within the consumer debt servicing industry. Upon closing of the transaction, the combined company will adopt the name Unifund Financial Technologies and is expected to be listed on Nasdaq under the ticker symbol (UFND). Based on current projections, the pro forma enterprise value of the combined company is estimated to be approximately $232M. This transaction is expected to be supported by a 1.5M share bonus pool. The bonus share pool is expected to be funded via founder shares held by Everest Consolidator Sponsor, LLC, Everest's sponsor, as an incentive to retain the targeted $60M in Everest's trust account. Pro forma for the transaction and based on current projections, the combined company is expected to have approximately $57M of cash. Existing equity holders of Unifund are expected to roll 100% of their equity holdings into the combined company. The transaction is expected to close as early as the fourth quarter.

08:12 EDT Cabaletta Bio appoints Tomasello to board of directors - Cabaletta Bio announced the appointment of Shawn Tomasello to its Board of Directors. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma between 2015 and 2018.

08:11 EDT Lovesac appoints Kawaja as Chief People Officer - The Lovesac Company announced that Carly Kawaja has been named Chief People Officer, CPO, effective July 17, 2023. She will report to President and Chief Operating Officer, Mary Fox. In this role, Kawaja will be responsible for leading the vision, strategy and operations of Lovesac's talent management including associate experience, rewards, talent acquisition, development, diversity, inclusion and belonging. Prior to Lovesac, Kawaja led the Human Resource organization at Athleta from 2019 to 2023.

08:09 EDT Bridger Aerospace to acquire 12 aircraft from Bighorn for $39M - Bridger Aerospace Group Holdings has entered into a definitive purchase agreement with Bighorn Airways. Bridger will acquire Bighorn's fleet of 12 aircraft used for wildfire smoke jumping as well as special mission transport and delivery for government customers. The transaction, valued at $39M, is expected to close by the end of September 2023 and is subject to normal and customary closing conditions. The acquisition will be financed through a combination of cash and stock, with the majority of consideration paid to the sellers in the form of stock. Bighorn's fleet of 12 aircraft includes three Bombardier Dash 8 featuring a 7500 lbs. payload capacity, a range of 1200 miles and the capability of low-level flights for para cargo operations. Bighorn also operates four Casa 212-200 and five Dornier 228-100 twin turboprop aircraft capable of short takeoff and landing. Bighorn is one of only a few air carriers that are approved by the DoD Commercial Airlift Review Board, holds a DoD Facility Security Clearance and is a U.S. Special Operations Command certified air carrier. Bighorn also owns and operates the Sheridan, WY Fixed Base Operation/ For the year ending 2023, Bighorn is expected to generate pro forma revenue of $22 million, and adjusted pro forma EBITDA of $5 million. While the transaction is expected to be accretive to earnings after excluding transaction expenses and before anticipated synergies, the Company is not updating its guidance at this time. Bridger will provide further information on the outlook for the Company and the addition of Bighorn during its next quarterly earnings call.

08:08 EDT Myriad Genetics announces inclusion of breast density to MyRisk test - Myriad Genetics announced its MyRisk Hereditary Cancer Test with RiskScore now incorporates breast density using Tyrer-Cuzick version 8 to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer. Breast density plays a critical role in breast cancer screening and diagnosis. The Federal Drug Administration recently updated mammography regulations requiring mammography facilities to notify patients about the density of their breasts by September 2024. The incorporation of this critical piece of information into MyRisk with RiskScore, and Myriad's recently launched cancer risk assessment program, is expected to help providers and their imaging networks offer more personalized patient care and detect breast cancer in its early stages, when there is the greater chance of a cure.

08:07 EDT PaxMedica reports results from PAX-101 Phase 3 African sleeping sickness Study - PaxMedica announced positive top line data for the Company's PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis, S1 TBR HAT. The conclusions of the study confirmed that the retrospective, non-randomized, externally controlled, interventional efficacy and safety study of suramin for the treatment of Stage 1 TBR HAT demonstrated better health outcomes when compared with a natural history control group of patients evaluated and treated from 1900-1910, prior to the availability of suramin in Africa. PaxMedica is expecting to file an NDA with the U.S. Food and Drug Administration for the use of PAX-101 to treat Stage 1 African Sleeping Sickness, in 2024. If approved, suramin will be the first drug indicated for the treatment of TBR HAT in the United States, and would potentially qualify PaxMedica to receive a Priority Review Voucher under the Neglected Rare Tropical Disease Program in section 524 of the Food, Drug, and Cosmetics Act.

08:06 EDT McKesson increases quarterly dividend 15% to 62c per share - The board of directors of McKesson declared a regular dividend of 62c per share of common stock, a 15% increase from 54c per share in the prior quarter. The dividend will be payable on October 2 to stockholders of record on September 1.

08:05 EDT True Velocity acquires suppressor manufacturer Delta P Design - TV Ammo, True Velocity, announced it has acquired advanced suppressor technology company Delta P Design. The strategic acquisition, approved by the True Velocity Board of Directors earlier this month, further strengthens the company's portfolio of American-made advanced, lightweight ammunition technology and next-generation weapon systems. "True Velocity owns world-class ammunition technology, world-class machine gun technology and, now with the acquisition of Delta P, world-class suppressor technology," said True Velocity President and Lone Star Future Weapons Chairman Craig Etchegoyen. "The only rule we have, when it comes to providing the very best technology to our warfighters, is that it must be American-made. With the acquisition of Delta P, we now have the ability to provide our warriors with superior ammunition, superior weapons and superior suppressors, all made here in America." As previously announced on November 1, 2022, TV Ammo entered into a business combination agreement with Breeze Holdings Acquisition Corp.

08:03 EDT IceCure Medical announces regulatory approval of ProSense System in Canada - IceCure Medical, announced that Health Canada, the Canadian government's regulatory agency, has approved IceCure's ProSense System, disposable cryoprobes, and introducers as cryosurgical tools for indications including tumors - ablation of benign and malignant tumors of the lung, liver, kidneys, and musculoskeletal system, and benign tumors of the breast; General surgery; palliative intervention; and ther surgeries.

08:00 EDT Spotify announces new pricing structure, Premium Single to cost $10.99/month - Spotify announced: "Since launching in 2008, Spotify has innovated and invested to build the best audio experience for you and your favorite artists and creators. We have continually revealed new opportunities for fans and creators to connect through the power of our platform, from discovery tools like our new AI DJ, to fan-favorite shared experiences like Blend and the introduction of podcasts and audiobook content. With 200+ million Premium subscribers, we're also proud to be the world's most popular audio streaming subscription service, giving Premium users access to on-demand and ad-free music listening, offline music downloads, and quality music streaming. The market landscape has continued to evolve since we launched. So that we can keep innovating, we are changing our Premium prices across a number of markets around the world. These updates will help us continue to deliver value to fans and artists on our platform." Spotify said that in the U.S., the new prices are: $10.99/month for Premium Single, $14.99/month for Premium Duo, $16.99/month for Premium Family, and $5.99/month for Premium Student. Reference Link

07:42 EDT Western Alaska Minerals reports assays from Waterpump Creek CRD - Western Alaska Minerals reports its first assay results from the initial phase of its second-year drilling program on the 100% owned Waterpump Creek Carbonate Replacement Deposit. Highlights: Infill drill hole WPC23-0029 intersected two high grade zones: 19.4 meters of 158 gpt Ag, 5.3% Pb and 11.5% Zn from 145.1 to 164.5 meters; Including 3.0 meters of 253 gpt Ag, 9.7% Pb and 15.9 % Zn from 145.1 to 148.1 meters. 2.9 meters of 173 gpt Ag, 6.7% Pb and 13.9% Zn from 176.0 to 178.9 meters. The hole was lost due to drilling conditions and left in mineralization. 2023 drilling at Waterpump Creek confirms continuous mantos of massive sulfide. Infill drilling will provide sufficient data points to enable to move toward a preliminary resource estimate at WPC. "Drilling at Waterpump Creek continues to produce impressive assay results that reinforce the high-grade nature of this part of the CRD system," states Kit Marrs, CEO of Western Alaska Minerals. "This infill hole in particular, expands the width by 28 meters, and contains grades and textures that closely resemble those found in WPC22-18, suggesting continuity of a major system".

07:36 EDT Monarch Mining signs royalty buyback option agreement with Gold Royalty - MONARCH MINING (GBARF) has entered into a royalty buyback option agreement with Gold Royalty (GROY) regarding the McKenzie Break, Swanson and Croinor properties. Monarch will have the right, exercisable for a period of 24 months, to repurchase up to a 1% NSR for each of the McKenzie Break royalty, Swanson royalty and Croinor royalty for the consideration provided below. In order to exercise the Buyback Right, Monarch, together with the eventual purchaser or purchasers of any Property, must deliver to Gold Royalty a written notice of election to exercise such right, with an agreement that would establish the terms and conditions of the exercise of such option to be entered into among Gold Royalty and the Purchaser. The Buyback Consideration is payable in cash or in voting shares of the Purchaser at the sole election of Gold Royalty and is as follows: For a period of 12 months following the buyback: $2 million in cash for each Property for which the Buyback Right is exercised; or $2.5 million in voting shares of the Purchaser. For a period starting on the first day following the end of the Initial Period and ending on the 24th month following the buyback: $2.5 million in cash for each Property for which the Buyback Right is exercised; or $3 million in voting shares of the Purchaser.

07:35 EDT Camping World set to acquire Mount Comfort RV in Greenfield, Indiana - Camping World Holdings announced that it is set to acquire Mount Comfort RV in Greenfield, Indiana, predominantly selling Forest River, Coachmen, Tiffin, Newmar, and Winnebago products. The transaction is anticipated to close in the fourth quarter of 2023 and will increase the Company's Indiana location count to three.

07:34 EDT Biodexa regains compliance with NASDAQ minimum bid price requirement - Biodexa Pharmaceuticals announced today that, on July 20, 2023, it received a notification from The Nasdaq Stock Market confirming the Company has cured the previously disclosed bid price deficiency, and that the Company is in compliance with all applicable listing standards. The Company's securities will continue to be listed and traded on Nasdaq and the previously announced hearing with the Nasdaq Hearing Panel is cancelled. Nasdaq further notified the Company that it will be subject to a Mandatory Panel Monitor for a period of one year from July 20, 2023.

07:32 EDT GH-CCMH selects Vitalhub for TREAT Client Information System - VitalHub announced a partnership with The Garry Hurvitz Centre for Community Mental Health at SickKids to implement their TREAT Client Information & Care Coordination software. This collaboration marks a significant milestone in advancing client care and streamlining operations at GH-CCMH.

07:31 EDT SomaLogic announces partnership with Dante Genomics - SomaLogic Operating announced its partnership with Dante Genomics, a global leader in genomics and precision medicine, to offer a comprehensive solution for proteomics testing at scale in Europe. Dante will be the first SomaLogic authorized site in Italy. Dante Genomics will run SomaLogic's technology out of its laboratory in Italy, providing proteomics services for the European market. SomaLogic's 7,000-plex SomaScan Platform can be applied across research and discovery. It can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. SomaLogic and Dante Genomics will partner to offer one of the first multiomic capabilities to support clinical research discovery, expanding the databases and total addressable market for both companies.

07:25 EDT Labcorp offers menopause testing through Labcorp OnDemand - Labcorp (LH) announced it now offers menopause testing through its Labcorp OnDemand digital health platform. The test is part of a suite of more than 50 curated tests available to consumers. Once purchased, specimens can be collected at one of over 2,000 Labcorp patient service centers nationwide, including over 400 Labcorp at Walgreens (WBA) locations.

07:19 EDT Public Storage to acquire Simply Self Storage BREIT for $2.2B - Public Storage (PSA) and Blackstone Real Estate Income Trust (BX) announced an agreement for Public Storage to acquire Simply Self Storage BREIT for $2.2B .The portfolio comprises 127 wholly-owned properties and 9 million net rentable square feet that are geographically diversified across 18 states and located in markets with population growth that has been approximately double the national average since 2018. Approximately 65% of the properties are located in high-growth Sunbelt markets. ..and unlock additional opportunities for growth and value creation. This acquisition reflects Public Storage's continued execution of its opportunistic growth strategy. Since 2019, Public Storage has expanded its portfolio by approximately 55 million net rentable square feet, or 34%, through $10.6B of acquisitions, development, and redevelopment, including Simply and additional properties previously announced as under contract.

07:13 EDT Quince to acquire EryDel and Ataxia-Telangiectasia - Quince Therapeutics announced that the company has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments. EryDel has developed an autologous intracellular drug encapsulation AIDE technology and a Phase 3 lead asset, EryDex, targeting a rare fatal pediatric neurological disease, Ataxia-Telangiectasia or A-T, which currently has no approved treatments. Upon completion of the transaction, EryDel stockholders will own approximately 16.7% of the combined company and will be entitled to up to $485M upon the achievement of development, regulatory, and commercial milestone payments, with no royalties. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is subject to certain regulatory approvals and other closing conditions and is expected to close in the third quarter of 2023...Strong balance sheet with approximately $87.6M in cash, cash equivalents, and short term investments as of June 30 , to provide funding for operating requirements into 2026. Potential to out-license ex-U.S. regional territories to provide runway through regulatory approval of EryDex. Plan to enroll first patient in global Phase 3 trial of EryDex in second quarter of 2024 with NDA submission targeted by end of 2025 SPA in place with FDA for a single global Phase 3 clinical trial of EryDex expected to be sufficient for NDA submission, assuming positive study results. Upon completion of the stock-for-stock upfront exchange, EryDel stockholders will own a maximum of approximately 16.7%, or 7,250,352 shares, of the combined company. The transaction agreement includes up to $485M in potential total downstream cash payments, including up to $5M in development milestones, $25M at NDA acceptance, $60M in approval milestones, and $395M in market and sales milestones, with no royalties paid to EryDel stockholders. The transaction will include the assumption of EryDel's $13 million European Investment Bank (EIB) loan with scheduled payments beginning in the second half of 2026. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is subject to certain regulatory approvals and other closing conditions and is expected to close in the third quarter of 2023.

07:11 EDT Microbix Biosystems presents results of STI Test Controls at AACC - Microbix Biosystems announces that it is presenting results of its Quality Assessment Products for supporting the clinical use and accuracy of multiplex tests for four of the most prevalent sexually-transmitted infections at the American Association of Clinical Chemistry, AACC, conference taking place in Anaheim, California July 23 to 27, 2023. At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases. Also at AACC, Microbix will present a poster titled "Evaluating the Performance of Emerging STI Point of Care Assays Using Novel, Room Temperature Stable CT/NG/TV/MG Positive Swab Quality Control Materials." The poster reviews the performance of novel PROCEEDFLOQ QAPs to support the clinical use and accuracy of multiplex PCR tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium - four of the most prevalent STIs.

07:09 EDT Wabtec receives orders for 3,500 new Generation 3 Collision Avoidance Systems - Wabtec announced the company received a series of orders for 3,500 of its new Generation 3 Collision Avoidance Systems from three major global mining companies. The capabilities of the new system will drive performance and safety improvements at the customers' mining operations.

07:08 EDT AEON Biopharma closes business combination with Priveterra Acquisition - AEON Biopharma (AEON) announced the closing of its previously announced business combination with Priveterra Acquisition (PMGM). Upon the closing of the merger, Priveterra changed its name to "AEON Biopharma, Inc." and transitioned the listing of its securities to the New York Stock Exchange American, where its common stock and warrants will now be listed under the symbols AEON and AEON WS, respectively. In addition, AEON announced the closing of its previously announced funding arrangements of up to $125 million. The funding includes approximately $50 million of committed financing from existing and new AEON investors, as well as the cash remaining in Priveterra's trust account after redemptions. The combined company will be led by AEON's team of biotechnology industry veterans, including Marc Forth as Chief Executive Officer and Jost Fischer as Chairman of the Board of Directors. "The team and I are excited to complete these transactions as we continue our progress on developing a therapeutic-only botulinum toxin," commented Mr. Forth. "The capital we have raised through these recent transactions will help fund our clinical development of ABP-450 to treat a number of debilitating medical conditions, including episodic and chronic migraine, cervical dystonia and gastroparesis. We expect to deliver on several key clinical milestones from certain of these programs over the next 18 months, including announcing topline data from the ongoing Phase 2 study for episodic migraine in the fall of this year, topline data from the ongoing Phase 2 study for chronic migraine in 2024, and initiation of a pivotal Phase 3 study for cervical dystonia in 2024. In addition to our progress in the clinic, the IND has been cleared by the FDA for a planned Phase 2 study of ABP-450 to treat gastroparesis and we are conducting preclinical studies for the treatment of posttraumatic stress disorder. We look forward to our first major data announcement as a public company later this fall."

07:06 EDT Lensar completes installation of multiple Ally Systems in ophthalmology groups - Lensar announced that it has completed the installation of multiple Ally Systems in five private equity-owned ophthalmology groups, including EyeSouth Partners' network. EyeSouth Partners is one of the largest PE-owned ophthalmic focused, premier networks in the U.S., with 35 practices, 19 surgery centers, and 290 doctors providing medical and surgical eye care services at over 160 locations. EyeSouth's stated objective is to enable physicians to focus on patient care, while bringing business expertise and financial and operational efficiencies to individual practices in its network. The company sees the adoption of the Ally System by EyeSouth Partners, and by four other PE-owned ophthalmology groups, as a strong sign of appreciation of this recently launched system. Several PE-owned groups, including EyeSouth Partners, have installed ALLY systems in multiple operating rooms within their practices or have indicated an intention to acquire additional systems, which the company attributes to Ally's procedure speed and operational efficiency.

07:05 EDT Immatics announces $35M equity investment by Bristol-Myers - Immatics (IMTX) announced that Bristol Myers Squibb (BMY) has made a $35M equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.46. Additionally, Bristol Myers Squibb has the right to appoint a member to the Immatics Scientific Advisory Board.

07:04 EDT Solaris Resources reports assay results from Warintza Project - Solaris Resources is pleased to report assay results from a series of holes aimed at growing mineral resources at the Warintza Project in southeastern Ecuador. Highlights: Warintza East was discovered in July 2021, with eight drill holes included in the Warintza Central Mineral Resource Estimate in April 2022. Subsequent drilling has significantly expanded the dimensions of the deposit, with drilling targeting further resource growth to the north, northeast, east and southwest. SLSE-27 was collared on the eastern limit of the Warintza East drill grid and drilled vertically to the limit of the KD-200 rig, returning 132m of 0.60% CuEq from near surface within a broader interval of 246m of 0.55% CuEq, bottoming in mineralization and remaining open at depth; SLSE-26 was collared 100m north of SLSE-27 and drilled vertically to the limit of the KD-200 rig, returning 212m of 0.52% CuEq within a broader interval of 310m of 0.45% CuEq from surface, ending in mineralization and remaining open at depth Step-out and deeper drilling is planned with two platforms under construction and a further six scheduled to extend the drilling grid to the north, northeast, east, and southwest; Warintza Southeast was discovered in May 2023 as a distinct, higher-grade porphyry center to the south of Warintza East beyond the limit of the MRE and offers potential to add higher-grade mineral resources, with deeper drilling underway and significant step-outs to the southeast planned. These holes follow discovery hole SLSE-28, which returned an open-ended interval of 301m of 0.65% CuEq in a favourable andesite porphyry host, and helps establish the geometry of the upper part of the system and vectors for further drilling; SLSE-29 was collared east of SLSE-28 and drilled southeast to the limit of the KD-200 rig through a less receptive intermineral diorite porphyry, returning 175m of 0.50% CuEq within 289m of 0.40% CuEq from near surface, with the final 105m averaging 0.60% CuEq and open to depth; SLSE-30 was collared west of discovery hole SLSE-28 and drilled southeast to the limit of the KD-200 rig, returning 30m of 0.53% CuEq from near surface within a broader interval of 275m of 0.48% CuEq, with the final 41m averaging 0.60% CuEq and remaining open to depth; Deeper drilling targeting extensions of higher-grade intervals noted at the end of each hole is underway and two additional platforms are under construction for step-outs 250m and 500m to the southeast where XRF values of 0.3% to 0.5% Cu in andesite porphyry were recorded.

07:03 EDT Tonix Pharmaceuticals announces data on TNX-601 ER, TNX-4300 - Tonix Pharmaceuticals announced data supporting the memory- and cognition-enhancing effects of two Tonix drug candidates, TNX-601 ER and TNX-4300, the single-isomer of tianeptine. TNX-601 ER is being tested in the potentially pivotal Phase 2 UPLIFT1 trial for the treatment of major depressive disorder, with topline results expected in the first quarter of 2024. TNX-4300 is in preclinical development for mood disorders, Alzheimer's disease and Parkinson's disease. The findings reported show that tianeptine and estianeptine improve memory and cognition as measured in the rat Novel Object Recognition test. The finding that estianeptine is responsible for improving memory and cognition suggests a role for PPAR-beta/delta activation in memory. "The memory- and cognition-enhancing effects of racemic tianeptine and estianeptine seen in the NOR test are consistent with human clinical studies in which racemic tianeptine treatment improved cognition and memory in patients with Alzheimer's disease and depression6 and in patients with bipolar disorder,7" said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "We recently reported that estianeptine induces neuroplasticity in cell culture.2 The new findings indicate that estianeptine also improves memory and cognition in the in vivo rat NOR test. We believe that together these findings support the development of tianeptine and estianeptine in psychiatric and neurodegenerative diseases. Tianeptine's ability to restore atrophied neuronal connections in animals2 suggests the potential to achieve durable outcomes."

07:02 EDT Syndax and Incyte report topline data from the pivotal AGAVE-201 trial - Syndax Pharmaceuticals (SNDX) and Incyte (INCY) announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease, or GVHD, following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts, with patients treated with axatilimab at doses of 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks and 3.0 mg/kg every four weeks demonstrating overall response rates, or ORR, within the first six months of treatment of 74%, 67% and 50%, respectively. Responses were achieved across key patient subgroups, including those with prior exposure to ruxolitinib, belumosudil and/or ibrutinib. Based on these results, and pending agreement from the FDA, Syndax and Incyte intend to submit a Biologics License Application to the FDA by year-end 2023. The AGAVE-201 pivotal study enrolled a total of 241 patients across 121 sites in 16 countries. Patients enrolled in the trial had received a median of four prior systemic therapies with 74% having previously received ruxolitinib, 23% having previously received belumosudil and 31% having previously received ibrutinib. 54% of these patients had at least four organs involved at baseline including 45% with lung involvement.

07:02 EDT Steakholder Foods enters MOA with GCC-based governmental body - Steakholder Foods announced that it has entered into a Memorandum of Agreement for Strategic Cooperation with an accredited GCC-based governmental body as Steakholder Foods' strategic partner, to advance food security efforts through the application of Steakholder Foods' groundbreaking 3D printing technology. Commencing with an investment by the strategic partner in the construction of a pilot plant to produce printed hybrid-fish products, the MOA eventually aims to create a first-of-its-kind large-scale production facility in the Persian Gulf region. The agreement foresees a material initial down payment to Steakholder Foods for the procurement of its 3D-printer technologies, followed by a milestone-based sales and procurement plan for industrial-scale output. The MOA is intended to contribute to the scalability of Steakholder Foods' 3D-printed food technology in territories in the Gulf Cooperation Council, which represents the economic union between Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.

06:53 EDT Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar - Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion for marketing authorization for "first-of-a-kind" biosimilar natalizumab developed by Polpharma Biologics. "The authorization covers treatment as a single disease-modifying therapy in adults with highly active relapsing-remitting multiple sclerosis, the same indication as approved by the EMA for the reference biologic. Sandoz entered into a global commercialization agreement for biosimilar natalizumab with Polpharma Biologics in 2019. Under this agreement, Polpharma Biologics will maintain responsibilities for development of medicine, manufacturing, and supply of drug substance. Through an exclusive global license, Sandoz has the rights to commercialize and distribute it in all markets," the company stated.

06:50 EDT Brown & Brown announces agreement to acquire assets of NEEE - J. Scott Penny, chief acquisitions officer of Brown & Brown and Ralf H. "Goober" Schaarschmidt II and Todd Wood, the owners of New England Excess Exchange, or NEEE, announced that Bridge Specialty Group has entered into an agreement to acquire the assets of NEEE. The transaction is expected to close in August 2023, subject to certain closing conditions. Established in 1981 in Vermont, NEEE has grown to become a leading wholesale MGA providing commercial and personal lines insurance solutions for qualified independent retail brokers throughout New England, Tri-State and Mid-Atlantic regions.

06:44 EDT Cian announces delisting of its shares in the NYSE - Cian announced that, following its review of the determination of the staff of the New York Stock Exchange Regulation to delist the Company's American depositary shares, each representing one ordinary share of the Company, from NYSE, a Committee of the Board of Directors of the NYSE. The Company was notified of the Final Delisting Decision on July 21, 2023. On that same date, the NYSE filed a Form 25 notification of removal from listing with the SEC. As previously announced, on March 15, 2023, the Company received a written notice of the delisting determination by the Staff. The removal of the ADSs from listing on the NYSE will become effective on July 31 ten days after the filing of the Form 25 notification of removal from listing. The Company does not expect the delisting to have any immediate effect on the terms of the ADSs under its ADS program, which will continue to exist in their current form. The trading of the Company's ADSs on the Moscow Exchange is unaffected and continues as usual.

06:32 EDT CGI Inc. to invest $1B on expansion of AI capabilities - CGI Inc. announced the planned investment of $1B over the next three years to support the continued expansion of its Artificial Intelligence, or AI, services and solutions in partnership with clients seeking to responsibly move from experimentation to implementation while accelerating time-to-value from new AI technologies. CGI's investment plans will include expansion of the company's AI-related consulting services, responsible and ethical-use delivery platforms and accelerators, intellectual property AI-enablement, global employee hiring and training, and operational excellence efficiencies. The company also is accelerating its investments in CGI PulseAI, a hyper-automation, conversational AI, and decision engine platform that enables clients to drive growth and efficiency by unlocking the value of enterprise data and business processes. The platform-already in use within CGI's own operations-is a proprietary platform built to integrate seamlessly with any third-party partner tooling. Importantly, PulseAI already includes over 35 AI models that are pre-trained to deliver results with an over 90% accuracy rate.

06:07 EDT Belite Bio completes enrollment of pivotal global Phase 3 "DRAGON" trial - Belite Bio announced that enrollment of its pivotal global Phase 3 "DRAGON" trial for patients with Stargardt Disease, or STGD1, has completed. Tinlarebant is an oral, once daily retinol binding protein 4, or RBP4, antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1. The pivotal Phase 3 DRAGON trial is a randomized, double-masked, placebo-controlled, global and multi-center study, designed to evaluate the safety and efficacy of Tinlarebant in adolescent STGD1 patients. The DRAGON trial has global sites in 11 countries, including the U.S., the United Kingdom, Germany, France, Belgium, Switzerland, Netherlands, China, Hong Kong, Taiwan, and Australia. 90 patients have been enrolled in this study with a 2:1 randomization. The primary efficacy endpoint is slowing of lesion growth rate, along with the assessment of safety and tolerability. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in both the U.S. and Europe for STGD1. Topline data for Tinlarebant in the Phase 2 STGD1 study is expected in the Q4 and the interim data for the Phase 3 DRAGON trial is expected by mid-2024. In addition, Belite plans to have the first patient enrolled in the 2-year Phase 3 study (PHOENIX) of Tinlarebant in Geographic Atrophy, or GA, in the Q3.

06:04 EDT KBR awarded $1.9B contract to support NASA spaceflight programs - KBR announced it has been awarded a significant contract worth up to $1.9B for the continued support of NASA's human spaceflight programs, including the International Space Station, Artemis and Low Earth Orbit Commercialization. Under the terms of Integrated Mission Operations Contract III, or IMOC III, KBR will provide mission planning and preparation, astronaut and Mission Control Center flight controller training, real-time flight execution, and future exploration vehicle design and development services for all of NASA's human spaceflight programs as a part of NASA Johnson Space Center's Flight Operations Directorate. Additionally, KBR will aid software development services for the International Space Station Program Avionics and Software Office. Work will be performed at various agency locations including JSC, Marshall Space Flight Center and Kennedy Space Center. This contract has a base period of five years with two, two-year options, potentially lasting 9 years. The full suite of programs supported under this contract includes the International Space Station, Commercial Crew, Boeing Starliner, Orion, Space Launch System, Gateway, Human Lander System, Extravehicular Activity and Human Surface Mobility, and Low Earth Orbit Commercialization. This contract is a follow-on to IMOC II, which KBR has proudly supported for the past nine years.

05:38 EDT Spinal Stabilization to become public through BlueRiver Acquisition combination - Spinal Stabilization Technologies and BlueRiver Acquisition have entered into a definitive business combination agreement. Upon the closing of the proposed transaction between SST and BlueRiver, the combined company will operate as Spinal Stabilization Technologies and be listed on an approved stock exchange. Spinal Stabilization Technologies is a medical device company focused on developing and then commercializing a proprietary lumbar implant for nucleus pulposus replacement to alleviate certain types of lower back pain. SST's flagship product, the PerQdisc, is a lumbar intervertebral disc nucleus replacement. The PerQdisc is an investigational device in the U.S. and has not been approved by the FDA. The PerQdisc, a silicone-based prosthesis formed in-situ, is designed to emulate the natural function of the native nucleus pulposus, providing a motion-preserving surgical solution. SST's pioneering work has positioned it to be at the forefront of the market for Augmented Discectomy and Degenerative Disc Disease treatments. The combined company would have an estimated post-transaction enterprise value of approximately $302M, assuming a proposed future $40M equity raise and assuming 100% redemptions by BlueRiver public shareholders. Proceeds from the transaction, if any, will be used to execute on the company's business plan including funding the FDA pivotal trial and commercial expansion. The proposed PIPE is subject to market and other conditions, and there can be no assurance as to whether or when the PIPE equity raise may be completed, or as to the actual size or terms of the PIPE when and if committed and consummated. BlueRiver's and SST's respective boards of directors have approved the transaction, which is expected to close in the fourth quarter of 2023, or early 2024, subject to regulatory and shareholder approvals and the satisfaction of other closing conditions, including the completion of mutual due diligence and a committed PIPE or other mutually satisfactory financing resulting in net proceeds of at least $10M. SST shareholders will roll 100% of their existing SST equity holdings and are expected to own equity-linked securities representing approximately 70% of combined company on a non-fully diluted basis immediately following the closing of the proposed business combination, assuming 100% redemptions by BlueRiver's public stockholders and a proposed future $40.0 million PIPE raise. Additional information about the proposed transaction, including a copy of the business combination agreement and investor presentation, will be provided in a Current Report on Form 8-K to be filed by BlueRiver with the Securities and Exchange Commission. The combined company will file a registration statement with the SEC in connection with the transaction.

05:30 EDT AppHarvest files for Chapter 11 bankruptcy - AppHarvest announced that it is pursuing a financial and operational transition to enable the company to reduce its outstanding liabilities. Business operations will continue at the farms, including shipping product to top national grocery store chains, restaurants and food service outlets. To pursue its transition, AppHarvest has filed voluntary petitions for protection under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas. The company has also obtained a commitment from Equilibrium, the company's largest secured creditor, to provide approximately $30M of debtor-in-possession financing to provide the necessary liquidity to support operations at the AppHarvest Morehead, AppHarvest Richmond and AppHarvest Somerset farms during the Chapter 11 process. The DIP financing is subject to approval of the Court. AppHarvest is pursuing a transition of its AppHarvest Berea operations to AppHarvest's distribution partner, Mastronardi Produce, or one of its affiliates, in exchange for approximately $3.75M, additional incremental funding and support for the company's restructuring plan. This transition is subject to approval of the Court. AppHarvest is diligently working to restructure the operations at the company in an effort to maximize the value creditors can expect to achieve and to preserve jobs.

05:25 EDT Alnylam enters pact with Roche to develop, commercialize zilebesiran - Alnylam (ALNY) announced it has entered into a strategic agreement with Roche (RHHBY) to develop and commercialize zilebesiran, Alnylam's investigational RNAi therapeutic for the treatment of hypertension, which is currently in Phase 2 of development. The partnership allows for a bold development plan with the goal of disrupting the hypertension treatment paradigm globally while advancing Alnylam's P5x25 strategy. Roche provides Alnylam the benefits of an outstanding partner with a global footprint and a proven track record of developing and commercializing novel therapies in complex markets. Roche has a proven history of innovating and commercializing medicines building upon their extensive global footprint which may potentially enable zilebesiran to reach more patients with hypertension, a disease that affects more than 1.2B patients globally. In a Phase 1 study, zilebesiran, compared to placebo, was associated with dose-dependent reductions in serum angiotensinogen, or AGT, achieving tonic blood pressure control with consistent and durable blood pressure reduction throughout a 24-hour period, sustained up to six months after single doses of 200 mg. Zilebesiran also demonstrated an acceptable safety profile supporting continued clinical development. The safety and efficacy of zilebesiran are being investigated in Alnylam's KARDIA Phase 2 clinical program either as a monotherapy or in combination with one of three standard-of-care antihypertensive medications. Based on the positive Phase 1 data, zilebesiran could potentially be a best-in-disease treatment and provide transformational benefit, especially for patients with hypertension at high cardiovascular risk. Zilebesiran also has the potential to improve adherence to treatment due to its possible biannual subcutaneous dosing regimen. In addition, zilebesiran may be effective in additional potential cardiovascular indications with high unmet need. Under the terms of the agreement, Alnylam will receive an upfront cash payment of $310 million and is eligible to receive additional substantial near-term payments, including development milestone payments over the next few years, as well as regulatory and sales milestones, for a potential deal value of up to $2.8B. In addition, Alnylam is entitled to an equal profit share in the U.S., where Alnylam and Roche will co-commercialize zilebesiran. Roche obtained the exclusive right to commercialize zilebesiran outside the U.S. in exchange for low double digit royalties on net sales of zilebesiran outside of the U.S. Alnylam believes that this partnership will allow the companies to pursue a joint development plan and commercialization approach that has the potential to unlock the full value of zilebesiran. Additionally, Alnylam will lead a joint clinical development plan for the first indication with Roche's participation, which includes a cardiovascular outcomes trial prior to submission of zilebesiran for regulatory approval, with all development costs shared 40% by Alnylam and 60% by Roche. Roche may lead development for additional indications in the future.

05:17 EDT Philips sees FY23 comparable sales up mid-single-digits - The company said, "Based on Philips' improved performance in the first half of the year, solid order book, and the ongoing actions to improve execution, the company now expects to deliver mid-single-digit comparable sales growth and an Adjusted EBITA margin at the upper end of the high-single-digit range for the full year 2023, while uncertainties remain. The outlook excludes the impact of the ongoing discussion on a proposed consent decree beyond current assumptions, as well as ongoing litigation and the investigation by the US Department of Justice related to the Respironics field action."